CD8+ T lymphocytes of the vaccine group in the three tumor-bearing groups were significantly higher than those of the PBS group, indicating that the AD-HPV16/18/58 mE6E7 vaccine can significantly activate the immune effect of CD8+ T lymphocytes in mice and inhibit CD4+ T lymphocytes, promote the development and activation of tumor effector cells, enhance the antitumor CTL effect, and enhance the body's antitumor ability. Here, CD8A is linked to neoplasm.